A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease
Status:
NOT_YET_RECRUITING
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
The study is a Phase 2a, randomized, double-blind, placebo-controlled, sequential cohort study to evaluate the pharmacodynamics (PD), safety and pharmacokinetics (PK) of multiple doses of SRSD107 in participants with coronary arterial disease (CAD) and/or peripheral arterial disease (PAD) with aspirin as background concomitant therapy.